Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14UAW | ISIN: SE0007045414 | Ticker-Symbol: 5J3
München
05.06.25 | 08:13
0,033 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SCIBASE HOLDING AB Chart 1 Jahr
5-Tage-Chart
SCIBASE HOLDING AB 5-Tage-Chart

Aktuelle News zur SCIBASE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SCIBASE Aktie jetzt für 0€ handeln
MiSciBase Expands Further Through European Market with First Sales Order to customer in Italy174STOCKHOLM, June 4, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced its first...
► Artikel lesen
27.05.SciBase reaches milestone with over 300,000 patients tested with Nevisense203STOCKHOLM, May 27, 2025 /PRNewswire/ -- SciBase Holding AB ('SciBase') (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced a major...
► Artikel lesen
23.05.SciBase publishes the Annual report for 2024215STOCKHOLM, May 23, 2025 /PRNewswire/ -- SciBase hereby announces that the Annual report for 2024 is available at the Company's website www.scibase.com. A pdf-version of the annual report...
► Artikel lesen
14.05.Notice to attend the annual general meeting in Scibase Holding AB (publ)185STOCKHOLM, May 14, 2025 /PRNewswire/ -- Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to the annual general meeting to be held on 17...
► Artikel lesen
13.05.SciBase: Interim report198STOCKHOLM, May 13, 2025 /PRNewswire/ -- January 1 - March 31, 2025 The first quarter in figures Net sales were TSEK 8,856 (6,057), +46%. The loss after tax was TSEK 27,510...
► Artikel lesen
11.04.SciBase launches next generation Nevisense228STOCKHOLM, April 11, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, is proud to announce...
► Artikel lesen
25.02.Year-end report: SciBase291STOCKHOLM, Feb. 25, 2025 /PRNewswire/ -- January 1 - December 30, 2024 The fourth quarter in figures Net sales were TSEK 8,598 (5,764), +49%.The loss after tax was TSEK 17...
► Artikel lesen
25.02.SCIBASE: Year-end report5
21.02.SciBase: New study shows significant improved clinical accuracy with Nevisense for both US and German dermatologists286STOCKHOLM, Feb. 21, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today, that...
► Artikel lesen
30.01.SciBase continues US expansion, on-boards Several US Dermatology Practices that Specialize in Skin Cancer Detection232STOCKHOLM, Jan. 30, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that...
► Artikel lesen
28.01.SciBase: New review article highlights Nevisense effectiveness in identifying malignant skin lesions275STOCKHOLM, Jan. 28, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that...
► Artikel lesen
27.01.SciBase: Recalculation of warrants of series TO 2 following rights issue382STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April...
► Artikel lesen
23.01.SciBase: Nevisense (EIS) included in updated German (S1) imaging guidelines426STOCKHOLM, Sweden, Jan. 23, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today...
► Artikel lesen
23.01.SCIBASE: Nevisense (EIS) included in updated German (S1) imaging guidelines.2
14.01.SciBase announces final outcome of directed issue and rights issue428STOCKHOLM, Jan. 14, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") today announces the final outcome of the capital raise, consisting of a rights issue of units of approximately...
► Artikel lesen
13.01.SciBase announces outcome of directed issue and preliminary outcome of rights issue448STOCKHOLM, Jan. 13, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") today announces the preliminary outcome of the capital raise, consisting of a rights issue of units...
► Artikel lesen
03.01.SciBase: The Mayo Clinic, the leading US hospital, will test Nevisense in Pilot465STOCKHOLM, Jan. 3, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced today that...
► Artikel lesen
27.12.24Today the subscription period in SciBase rights issue begins624STOCKHOLM, Dec. 27, 2024 /PRNewswire/ -- Today, on December 27, 2024, is the first day of the subscription period in SciBase Holding AB's ("SciBase" or the "Company") rights issue of units...
► Artikel lesen
20.12.24SciBase letter from the CEO507STOCKHOLM, Dec. 20, 2024 /PRNewswire/ -- In 2024, SciBase has advanced its positions significantly and laid the foundation for continued growth, with a new organization in the US, success...
► Artikel lesen
20.12.24SciBase publishes prospectus523STOCKHOLM, Dec. 20, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") announced on November 12, 2024 that the Board of Directors has resolved, subject to the subsequent...
► Artikel lesen
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1